X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement equity awards effective February 27, 2026, granting options to purchase an aggregate of 24,000 shares to new employees under its 2019 Inducement Equity Incentive Plan.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement equity awards effective February 27, 2026, granting options to purchase an aggregate of 24,000 shares to new employees under its 2019 Inducement Equity Incentive Plan.

The options have a 10-year term, an exercise price of $3.44 (closing price on February 27, 2026) and vest 25% after 12 months, then monthly over 36 months, subject to continued employment and plan terms; grants were approved by the compensation committee per Nasdaq Listing Rule 5635(c)(4).

Argus Mar 3 session

-2.06% close to close Open Argus

Details

News Market Reaction – XFOR

In the Mar 3 session, XFOR declined 2.06%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement stock option grants covering 24,000 shares at an exerci...

Analysis

This announcement details routine inducement stock option grants covering 24,000 shares at an exercise price of $3.44, vesting over four years. It follows a period marked by substantial financings totaling $155.3M in gross proceeds and strategic restructuring to extend the cash runway. Investors may focus on execution of the 4WARD Phase 3 program, the company’s cash position from recent offerings, and any future updates that build on its post-approval commercialization efforts.

Key Figures

Inducement options granted: 24,000 shares Exercise price: $3.44 per share Option term: 10 years +3 more

Inducement options granted

24,000 shares

Options to purchase common stock granted to new employees

Exercise price

$3.44 per share

Equal to closing price on February 27, 2026

Option term

10 years

Contractual life of inducement stock options

Vesting period

4 years

Inducement options vesting schedule

Initial vesting cliff

25% after 12 months

Portion of options vesting after first year of service

Remaining vesting

Monthly over 36 months

Balance of options vesting cadence

Historical Context

5 past events · Latest: Feb 03

5 events

1. Feb 03

   Conference participation

   24h Move

   +0.5%

   Management participation at Guggenheim Emerging Outlook Biotech Summit with webcast access.

2. Feb 02

   Inducement grants

   24h Move

   +0.5%

   20,000 inducement options at $3.70 with standard four-year vesting terms.

3. Nov 05

   Conference participation

   24h Move

   -1.3%

   Participation in Guggenheim Healthcare Innovation Conference with fireside chat and meetings.

4. Nov 05

   Earnings and update

   24h Move

   -10.6%

   Q3 2025 loss, workforce reduction, and higher Phase 3 enrollment target disclosed.

5. Oct 27

   Public offering

   24h Move

   +1.9%

   Underwritten equity offering raising $155.3M gross with added pre-funded warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"These stock awards were granted as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 24,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $3.44 per share, which is equal to the closing price of X4’s common stock on February 27, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI^® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
IR@X4pharma.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did X4 Pharmaceuticals (XFOR) grant on February 27, 2026?

X4 granted options to purchase a total of 24,000 common shares as inducement awards to new employees. According to the company, the options carry a 10-year term and an exercise price equal to the Feb 27, 2026 closing price of $3.44.

How do the XFOR inducement options vest and when do employees receive shares?

The options vest over four years: 25% after 12 months, then monthly over 36 months. According to the company, vesting is contingent on the employee's continued employment on each vesting date under the award agreement.

What is the exercise price and term for the XFOR inducement options granted in 2026?

Each option has an exercise price of $3.44 and a 10-year term from grant date. According to the company, $3.44 equals the closing price of XFOR common stock on February 27, 2026.

Why did X4 Pharmaceuticals use the 2019 Inducement Equity Incentive Plan for these grants (XFOR)?

X4 used the 2019 Inducement Plan to grant equity awards exclusively to individuals not previously employed by the company. According to the company, this complies with Nasdaq Listing Rule 5635(c)(4) for new-employee inducement grants.

Who approved the XFOR inducement awards and what conditions apply to the options?

The company's Compensation Committee approved the inducement awards to new hires. According to the company, options are subject to the 2019 Inducement Plan and a binding award agreement with standard terms and employment-contingent vesting.